Related Experiment Videos
[Bladder involvement in HTLV-I associated myelopathy]
Abstract:
The HTLV-I infection was endemic in south western Kyushu. This human T-lymphotropic virus type I may cause HTLV-I associated myelopathy (HAM), a neurological disease characterized by a spastic paraparesis. And one of the minor diagnostic features of HAM is the presence of cystorectal disturbance. We experienced 35 HAM patients with a neurogenic bladder. A gradually progressive contracted bladder was observed in 3 of them. The main pathological finding in these patients was submucosal infiltration of lymphocytes. These findings suggest that immunologic mechanisms account for the development of bladder lesions.
Insights
Human T-lymphotropic virus type I (HTLV-I) infection can lead to HTLV-I associated myelopathy (HAM), causing bladder dysfunction. Lymphocyte infiltration in the bladder suggests immune mechanisms contribute to HAM-related bladder damage.
Area of Science:
- Neurology
- Virology
- Immunology
Background:
- Human T-lymphotropic virus type I (HTLV-I) infection is endemic in certain regions.
- HTLV-I is known to cause HTLV-I associated myelopathy (HAM), a neurological disorder.
- Cystorectal disturbances are a recognized, albeit minor, diagnostic feature of HAM.
Observation:
- Thirty-five patients with HAM and neurogenic bladder were studied.
- Three of these patients exhibited a gradually progressive contracted bladder.
- Pathological examination revealed submucosal lymphocyte infiltration in the affected bladders.
Findings:
- Submucosal lymphocyte infiltration is a key pathological finding in HAM patients with bladder lesions.
- Progressive bladder contraction was observed in a subset of HAM patients.
- The study links neurogenic bladder complications to HTLV-I infection.
Implications:
- Immunologic mechanisms are implicated in the development of bladder lesions associated with HAM.
- Understanding these mechanisms may lead to targeted therapies for HAM-related bladder dysfunction.
- This research highlights the systemic impact of HTLV-I beyond the central nervous system.